Skip to main content
Search

Peptide-drug conjugates as therapeutic modality in drug development 1

Part 1 of 2
Published on June 30, 2025   30 min

Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms

Please wait while the transcript is being prepared...
0:00
Hello, I'm Dr. Syed Faheem Askari Rizvi. I'm from the Center for Molecular Imaging School of Public Health, Xiamen University in China. Today, the topic of my discussion is Peptide-Drug Conjugates as Therapeutic Modality in Drug Development.
0:20
So the content of our talk is a little bit of self-introduction, research interests, then I will give a brief information about the background of my topic, about cancer, about peptide drugs, and about peptide-drug conjugates. Next, we will discuss about receptor-targeting peptides, which are currently undergoing clinical trials, as well as some that are FDA approved. Next, we will discuss about conjugation with fluorescence dyes, and conjugation with radionuclides, which also followed by the peptide-drug conjugates designed on the basis of pH-dependent linkers. Finally, I will summarize the conclusion of this whole talk.
1:07
So this is a brief introduction about me, my background, and my future career.
1:17
My research interests are dependent on the drug delivery and pharmacokinetics with broad research focus including but not limited to various medications used in the treatment of cancer, Alzheimer's disease, and on understanding the role of biopharmaceuticals as well as pharmacokinetics in elucidating the underlying importance in optimizing drug therapy. I have been an author of more than 40 international publications, and I have been working as an invited reviewer for various journals.

Quiz available with full talk access. Request Free Trial or Login.

Show
Hide

Peptide-drug conjugates as therapeutic modality in drug development 1

Embed in course/own notes